CAPN9

Across TCGA pan-cancer cohorts, CAPN9 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CAPN9 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CAPN9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CAPN9 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where CAPN9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.832	0.480	.002	31	view →
LUAD	DFS	Median	II,III,IV	0.690	0.966	.024	7	view →
LSCC	DFS	Median	All	0.629	0.806	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CAPN9–PDAC (OS)

Open the PDAC breakdown →